Advanced Bladder Cancer VL

The Landscape of Advanced Bladder Cancer: A Review of the Last 30-Years - Cora Sternberg

Details
Cora Sternberg joins Alicia Morgans at ASCO GU 2020 and discusses the significant advancements in the treatment of advanced bladder cancer looking back over the last 30 years. MVAC was regulatory approved as the first line treatment in metastatic bladder cancer thirty years ago. Cora discusses the recent progress that is offering significant improvements in the overall survival for those patients...

Enfortumab Vedotin for Advanced Urothelial Carcinoma - Jonathan Rosenberg

Details
Alicia Morgans is joined by Peter O’Donnell and Jonathan Rosenberg to discuss enfortumab vedotin (EV). This offers a new mechanism of action and is the first antibody-drug conjugate (ADC). This represents a targeted therapy and was studied in metastatic urothelial carcinoma. In reviewing the clinical data and side effects of the drug, the three clinicians highlight the effectiveness and tolerabili...

Updates on Bladder Cancer Clinical Trials ASCO GU 2020 - Matthew Galsky

Details
Joining Alicia Morgans is Matt Galsky to discuss the biggest updates in bladder cancer clinical trials. Building off of his overview of IMvigor130, KEYNOTE-361, and JAVELIN Bladder 100, Dr. Galsky provides insight on how he incorporates clinical data into his everyday practice and the direction he believes the field is moving towards in the future. Biographies: Matthew Galsky, MD Director of Genit...

Recent Advances in the Treatment of Metastatic Urothelial Cancer - Petros Grivas

Details
Ashish Kamat sits down with Petros Grivas to discuss the recent advances and clinical trials in second and third-line therapies in metastatic urothelial cancer. Biographies: Petros Grivas, MD, PhD , Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center Ashish Kamat, MD,...

Treatments in Development for Muscle-invasive Bladder Cancer - Min Yuen Teo

Details
Alicia Morgans, MD, MPH and Min Yuen Teo, MD, discuss areas of unmet need in bladder cancer treatment, including in the management of patients with non-metastatic muscle-invasive bladder cancer, as well as those who develop metastatic or progressive disease. At Memorial Sloan Kettering, Dr. Teo’s research group has focused on three themes: How to improve the efficacy of cisplatin-based chemotherap...

Advanced Bladder Cancer Clinic: Are you Ready? - Neal Shore

Details
In this 2019 LUGPA CME presentation by Neal Shore, he makes the case that now is the time to be developing your advanced bladder cancer clinics. There has been a tremendous amount of advancement in frontline metastatic bladder cancer and Neal Shore highlights some of the rapid changes in the field of both metastatic locally advanced and high-risk bladder cancer. PD receptor blockers, FGFR-targetin...

Immunotherapy and Chemotherapy Use in Patients with Metastatic Bladder Cancer - Ronac Mamtani and Ravi Parikh

Details
In this conversation, Ronac Mamtani and Ravi Parikh join Alicia Morgans to discuss their recent work on bladder cancer outcomes and effectiveness research. They discuss immune checkpoint therapy versus carboplatin chemotherapy in patients with metastatic urothelial cancer (mUC). They also discuss the "Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cance...

Circulating Tumor DNA in Urothelial Cancer - Interview with Bishoy Faltas

Details
Bishoy Faltas and Charles Ryan discuss some of Bishoy's work using cell-free DNA, or circulating tumor DNA, and what it means in urothelial cancer today. Circulating tumor DNA is DNA that's shed by the tumor into the bloodstream, and the advantage of the current technology and the evolving technology is that we can actually get that DNA. In this work being discussed Bishoy and colleagues are focus...

Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas

Details
Alicia Morgans hosts Bishoy Faltas in a discussion about a Nature Communications publish article Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling which Bishoy was a co-author on with Brian D Robinson et al. In this study an integrated analysis of whole-exome and RNA sequencing of upper tract urothelial carcinoma (UTUC) was performed...

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky

Details
Professor Matt Galsky joins Alicia Morgans to share details of an analysis looking at FGFR mutations in patients who have received checkpoint inhibitor therapy on clinical trials. In this study, Matt Galsky and colleagues examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. Using data derived from two clinical trials exploring C...